Notable Labs, Ltd. (NTBL)
(Delayed Data from NSDQ)
$0.49 USD
+0.01 (1.77%)
Updated Aug 8, 2024 03:54 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NTBL 0.49 +0.01(1.77%)
Will NTBL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTBL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTBL
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
NTBL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NTBL
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Notable Labs Advances with Phase 2 Trial for Volasertib
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Notable Labs receives FDA clearance to proceed further with volasertib study
Notable Labs receives FDA clearance to proceed with Volasertib phase 2 study